Novartis Investigative Site

Basingstoke, Hampshire RG24 9NA

1 studies enrolling now · 8 studies all time

What they study most

Acute Heart Failure, Acute Myocardial Infarction, Atherosclerosis, Chronic Heart Failure With Reduced Ejection Fraction, Diffuse Cutaneous Systemic Sclerosis, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Psoriatic Arthritis

Studies at this site

• A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis — Recruiting now
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early